Skip Navigation Links
 Venue 
 تاریخ های مهم 
 Registration 
 Pre Registered 
 Abstracts 
 برنامه همایش 
 Exhibition 
 Personal page 
  
 Archive 
                             دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد        شب بهاری چشم پزشکی با رحیم شهریاری       دومین همایش بهاره چشم پزشکی
Skip Navigation Links
        مکان برگزاری
        تاریخ های مهم
        ثبت نام
        ثبت نام شدگان
        مقالات
        برنامه همایش
        نمایشگاه
        صفحه شخصی
        جستجوی سخنران
        آرشیو
 
مقاله Abstract


Title: Retinal Vasoproliferative Tumors (VPTs) treatment: A 15-year retrospective study in a tertiary referral center in Iran
Author(s): Masood Naseripour, Navid Abolfathzadeh, Ahad Sedaghat, Amirpooya Alemzadeh
Presentation Type: Poster
Subject: Retina and Retinal Cell Biology
Others:
Presenting Author:
Name: Navid Abolfath Zadeh
Affiliation :(optional) Eye Research Center, Rassoul Akram Hospital, Iran University of Medical Sciences, Tehran, Iran
E mail: navid.ab@gmail.com
Phone:
Mobile: 09127969425
Purpose:

To report the outcomes of different treatment modalities for vasoproliferative tumors (VPTs) of the ocular fundus in terms of anatomical and functional properties of tumor in a single referral ocular oncology center in IRAN.

Methods:

The clinical charts of all patients diagnosed with VPT from 2002 to 2017 were retrospectively reviewed. Clinical features, types of treatment, outcomes and complications were evaluated. Patients were divided to plaque radiotherapy group (A) and non-radiation group (B) (including Photodynamic therapy (PDT), Cryotherapy, Barrier laser photocoagulation and Vitrectomy).

Results:

We enrolled 46 eyes of 46 patients diagnosed with VPT in this study. Ru-106 plaque radiotherapy was done in 25 (54.3%) cases. Twenty eight patients (58.6%) were female. Mean age of patients was 40.9 ± 13.1 and 32.5 ± 13.3 in group A and B respectively (P=0.03). Eighteen (39.1%) had primary and 28 (60.9%) had secondary VPTs. In Group A, four different types of Ru-106 plaques were applied. Total apex dose (Gy) was 98.95±14.40 and total sclera contact dose (Gy) was 412.26±113.66. In group B, three types of treatment were used as cryotherapy ±intravitreal bevacizumab in 7(33%), cryotherapy +vitrectomy in 10 (48%), and PDT in 4(19%) patients. Initial tumor thickness was 4.27 ± 1.10 mm in group A versus 4.40 ±1.45 mm in group B (P>0.05). Postoperatively, the mean tumor thickness decreased to 2.60 ± 0.63 mm in group A and to 2.56 ± 1.62 mm in group B (P<0.001 in both groups and P=0.9 between groups). Tumor regression was considered as at least 1 mm decrease in tumor thickness and decrease in subretinal fluid and macular exudation, which was achieved in both treatment groups (P=0.000). Visual acuity was less than 20/400 in 9 patients (36%) before treatment and 10 patients (45%) at last follow up in group A and in 10 patients (48 %) before and 11 patients (52%) at last follow up in group B. Complications occurred in 15 (60%) and 12 (57%) of patients in group A and B respectively.

Conclusion:

Both Ru-106 plaque radiotherapy and non-radiation treatments modalities were effective in management of VPTs and tumor regression. There was no statistically differences in visual outcomes.

Attachment: 25VPT - IRAVO 97.pptx





Last News

  - دومین ويژه نامه همايش بهاره چشم پزشكي منتشر شد
  -  شب بهاری چشم پزشکی با رحیم شهریاری
  - دومین همایش بهاره چشم پزشکی